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Abstract
Background: Tanzania switched the antimalarial first line to sulphadoxine-pyrimethamine (SP) in
2001 from ineffective chloroquine (CQ). By 2003 higher levels of SP resistance were recorded,
prompting an urgent need for replacing the first line drug with ACT, as currently recommended by
the World Health Organization. Despite this recommendation country-specific evidence-based
data to support efficacy and safety profile of ACT is still limited. A study on the efficacy and safety
of artesunate plus amodiaquine (AS+AQ) and artemether plus lumefantrine (AL)(Coartem®) was
carried out in 2004 with the view of supporting the National Malaria Control Programme in the
review of the policy in mainland Tanzania.
Methods: An in vivo efficacy study was conducted at Ipinda and Mlimba health facilities between
May and November 2004. The study recruited children aged 6–59 months presenting with
symptoms of uncomplicated malaria, history of fever or an axillary temperature ≥37.5°C; mono
infection with Pasmodium falciparum (2,000–200,000 parasites/μl). Patients were randomized to
received either SP or amodiaquine monotherapy or treated with standard doses of AS+AQ in
Mlimba and Coartem in Kyela and followed-up for 28 days to assess treatment responses. This
study reports results of the combination therapies.
Results: A total of 157 children (76 in Mlimba and 99 in Kyela) who were enrolled in to the study
and treated with either AL or AS+AQ were successfully followed-up. Both combinations were
tolerated and effected rapid fever and parasite clearance. The crude ACPRs were 80 (87%) and 41
(63%) for AL and AS+AQ respectively. However, after PCR adjustments the corresponding figures
raised to 100% (n = 86) and 93.8% (n = 45) in AL and AS+AQ groups, respectively. The mean
haemoglobin improved moderately from day 0 to day 28 by 1 g/dl in AL and 0.4 g/dl in AS+AQ
treatment group and was statistically significant (p < 0.001 both).
Conclusion: These findings provide substantial evidence that AL is highly efficacious in areas of
high resistance of SP and supported the country's decision to switch from SP monotherapy to AL.
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Background
The emergence and spread of Plasmodium falciparum resist-
ance to commonly used antimalarials such as chloroquine
(CQ) and sulphadoxine/pyrimethamine (SP) has posed
major challenges to malaria control in sub-Saharan Africa.
In the face of escalated resistance to these widely used and
long utilized antimalarial the World Health Organization
(WHO) currently recommends the use of artemisinin
combination therapies (ACTs) as the first line treatment
of malaria in sub-Saharan Africa [1-3]. Several countries in
the region have started implementing the use of ACTs as
the first line drug. Despite these recommendations, coun-
try specific evidence-based data to support antimalarial
first line treatment policy change to ACTs is still lim-
ited[4].
In 2001, the Tanzanian Ministry of Health and Social Wel-
fare switched its first line drug from CQ to SP Prior to this
change, CQ has remained in use as the first line drug for
over 45 years and had recorded day 14 parasitological cure
rates of 10.3% [5]. A number of lessons were, therefore,
learnt after this policy revision. Some of these include,
poor acceptability of the new policy as health services pro-
viders and the general public at large were short of prepar-
edness to adopt the new policy[6,7]. In addition, there
were very few efficacious, safe and cheap drugs to be con-
sidered for first line. At the same time efficacy and safety
data on the few available drugs were missing. In the after-
maths of interim policy inception, several major steps
were taken including conducting invivo studies on efficacy
of SP and other newly registered antimalarials geared to
increase choices and preparedness should the need for
policy revision arise [8-10]. In this framework, therefore,
an invivo study was carried out on the efficacy of some
ACT drugs with a view of supporting the National Malaria
Control Programme (NMCP) in reviewing the antimalar-
ial drug treatment policy in Tanzania.
Methods
Study site and design
The study was conducted within the invivo efficacy testing
framework of the Tanzania NMCP/East African Network
for Monitoring Antimalarial (EANMAT). Two health facil-
ities took part in the study; Ipinda in Kyela District at the
boarder with Malawi and Mlimba in Kilombero District in
South-eastern Tanzania. This study was conducted in
2004 between January – June and March – October at
Ipinda and Mlimba health facilities, respectively. At both
sites malaria transmission is perennial and peaks between
May and July, after the long seasonal rainfall.
The WHO standardized protocol for the assessment of
therapeutic efficacy of antimalarial drugs (WHO 2000)
was used and the study included sick children who were
6–59 months age if they presented with history of fever in
the past 24 hours or axillary temperature of ≥37.5°C, and
mono-infection of P. falciparum count of 50–5,000/200
white blood cells (WBC) assumed to be 2,000–200,000
parasites/μl. Patients were excluded from the study if they
present with repeated convulsion, inability to take any-
thing orally, severe anaemia i.e. Hb ≤ 5 gm/dl, difficult in
breathing or patient with signs consistent with renal fail-
ure and patient's parent/guardian unwillingness to partic-
ipate.
Intervention
The patients were randomized to receive either mono-
therapy or the ACT according to the NMCP schedule of
sentinel testing. At Ipinda sentinel site SP and amodi-
aquine were used as the monotherapies and artemether/
lumefantrine (AL)(Coartem®) was used as the ACT while
artesunate and amodiaquine (AS+AQ) in an ad-hoc as ACT
and the same monotherapies were given at Mlimba. This
study reports only the outcome of both combination ther-
apies. AL was given to children according to bodyweight
as follows 20/120 mg tablet to those weighing 5–14 kg
and two tablets 40/240 mg to children with 15–24 kg. The
full course of treatment for all study patients in this group
consisted of 6-doses of AL that was given at 0, 8 and 16
hours, the remaining doses were given at 12-hourly inter-
vals for a total of three days. At Mlimba sentinel site
AS+AQ was given at a dose of 4 mg/kg and 10 mg/kg body
weight respectively. AS+AQ was given on day 0, 1 and 2
with only amodiaquine's dose reduced to 5 mg/kg body
weight on day 2. All treatments were supervised by study
nurse and patients were observed for 30 minutes in the
aftermath of drug intake. All patients who vomited within
30 minutes intervals were re-administered another full
dose of the same medicine. All treated patients were fol-
lowed for 28 days to assess clinical and parasitological
responses. Patients that did not turn up for scheduled
dose were visited at home by the study nurse on the same
day. Treatment outcomes were classified as early treat-
ment failure (ETF), late clinical failure (LCF), late parasi-
tological failure (LPF) and adequate clinical and
parasitological responders (ACPR) using the (WHO
2003) guidelines. Clinical therapeutic outcomes were
adjusted by genotyping the P. falciparum merozoite sur-
face protein 2 (msp2) and glutamate rich protein (glurp)
on admission (Day 0) and any day of infection recur-
rences (Day 7, 14, 21 or 28). Recrudescence was differen-
tiated from new-infections as described by Mugittu et al
2006 [11] only for patients who received ACTs due to cost
limitation. Under this assessment, only parasitaemia that
was confirmed by PCR as recrudescence was considered as
treatment failure and conversely, was considered as new
infection and counted as the ACPR.Malaria Journal 2007, 6:146 http://www.malariajournal.com/content/6/1/146
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Clinical and laboratory procedures
Patient follow up were scheduled on days 1, 2, 3,7,14, 21
and 28. On each visit, including day 0 under which
patient were enrolled. Clinical, parasitological and hae-
matological examinations were performed. Haemoglobin
level (Hb) was assessed using HemoCue® (Angelholm,
Sweden) and the Hb of ≤5 g/dl was considered as severe
anaemia. Parasitological examinations involved prepara-
tion of thick and thin blood smears from each patient and
examined by specialized microscopist from Ifakara Health
Research and Development Centre (IHRDC). Parasitae-
mia was expressed as count per 200 WBC of blood assum-
ing a normal leucocytes level of 8,000/μl.
Analysis
Data generated in patient's case record forms were entered
on FoxPro® database software version 7 (Microsoft Corpo-
ration, Redmond USA 2001) at Ifakara Health Research
and Development Centre (IHRDC). Data analysis was
performed using STATA® statistical analysis software pack-
age version 8 (Stata corporation, Collage Station TX, USA,
2003). Descriptive analysis was done and differences in
proportions of treatment outcome were compared using
chi square test for proportions. Student's t-test was
applied for continuous variables. Data on patients that
were excluded for different reasons and those that were
loss to follow up were not considered in the final analysis.
Results
Study profile and patient's records
A total of 99 and 76 patients were enrolled at Ipinda and
Mlimba health facilities, respectively. Table 1 summarizes
patient's mean age, body weights, clinical and haemato-
logical parameters at admission/enrollments. There were
18 patients who were loss to follow up; 7/99 (7%) in
Ipinda and 11/76 (14.5%) in Mlimba. Overall 92/99
(92.9%) patients in Ipinda (AL arm) and 65/76 (85.5%)
in Mlimba (AS+AQ arm) were available for the assess-
ment of therapeutic endpoints.
Treatment outcome
Both drugs were tolerated; there was no report of signifi-
cant Adverse Drug Reaction (ADR). Table 2 shows crude
and PCR corrected treatment rates of the test drugs. The
crude ACPRs were 80/92 (87%) and 41/65 (63%) for AL
and AS+AQ, respectively. After PCR adjustment however,
the corresponding figures rose to 100% (86/86) and
93.8% (45/48) in AL and AS+AQ respectively. Most of the
recurrent infections at both sites were due to LPF. Interest-
ingly, after genotyping all these were found to be due to
new infection. The study recorded only two recrudescent
infection, both of which in the AS+AQ. No recrudescence
was observed in the AL arm. Moreover, a total of 10 recur-
rent infections (six in AL and four in AS+AQ) could not be
unresolved even after repeated DNA extraction and PCR
amplification. When these 10 recurrent infections were
assumed to be recrudescence in the final analysis together
with the PCR corrected ones however, the ACPRs were
93.3% (83/89) in AL and 87.1% (54/62) in AS+AQ.
The mean haemoglobin improved moderately from day 0
to day 28 by 1 g/dl in AL and 0.4 g/dl in AS+AQ treatment
groups. The mean haemoglobin recovery after day 28 was
statically significant in both groups (p < 0.001 both).
Discussion
The main goal of this invivo ACT efficacy study was to sup-
port the establishment of evidence-based results that can
be used to change malaria treatment policy in Tanzania.
This study has demonstrated high therapeutic efficacy and
tolerability for a six dose regimen of AL and a 3-day course
of AS+AQ in southern Tanzania. Both crude and PCR-cor-
rected ACPRs for AL (87% and 100%) were higher than
those recorded in the AS+AQ (63.2% and 93.8%) arm.
The AL crude and PCR-corrected cure rates are more or less
similar to those recorded in Muheza Tanzania in 2005
(79% and 97.2%), [12] and in mult-country (Tanzania
inclusive) AL efficacy study (86.5% and 93.9%) [13].
The testing of each drug independently for each site was
due to the arrangements in place that required testing
each individual drug as part of antimalarial nationwide
drug testing allocation. This allows accumulation of evi-
dence of the performance of the ACT in different settings.
It can be argued that there are differences from place to
place related to the response to treatment that is observed
but treatment policies are formulated at regional or sub-
regional level hence the need to get regional summary
estimates. The sentinel system is a good approach toward
addressing that need. Secondly it will be very difficult to
sample all possible places where variation is being
expected and under the current malaria transmission
Table 1: Mean age, temperature, parasite density and haemoglobin on the day of enrollments
Sentinel site Measured parameters-Means (Standard Deviations [SD])
Age in years (SD) Body weight in Kg (SD) Temperature in °C (SD) Hb in g/dl(SD) Parasites/μl (SD)
Ipinda (n = 99) 2.3 (1.2) 11.9 (2.7) 38.9 (0.98) 9.7 (1.4) 43114.5 (40130.4)
Mlimba (n = 76) 2.1 (1.2) 11.3 (2.5) 38.2 (1.2) 8.7 (1.7) 49347.8 (48194.1)Malaria Journal 2007, 6:146 http://www.malariajournal.com/content/6/1/146
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intensity in Tanzania, it is hard to follow up enough
patients for all treatment groups in a single site during the
same transmission year [14].
An interpretation of the comparative efficacy of the two
drugs was not considered in our analysis. The reasons for
this approach are; first this study was not designed to
measure the differences between two test drugs but only
to get point estimates of the efficacy which also allows
monitoring of their performance overtime. Second, both
ACT drugs have high efficacy profiles in the region that in
principal would require huge sample size to be able to
show a comparative difference [12,15]. For this same rea-
son the direct comparison of the two ACTs in a rand-
omized trial is not an optimal approach of monitoring
drug efficacy in the programme's implementation setting
and the reliance of sentinel sites in a country, therefore,
becomes an efficient solution.
Conclusion
According to the current malaria treatment policy revision
guidelines (changing policy at >10% failure rate), both AL
and AS+AQ would be considered suitable drugs for first
line purpose since both recorded high PCR-corrected effi-
cacies i.e. 100% and 93.8%, respectively. However, it was
more rational to adopt AL as its efficacy is far above the
cut-off point, whereas AS+AQ efficacy is just 3 units
higher from the policy revision cut-off point and its useful
therapeutic life might be compromised sooner following
widespread use. In addition, the policy revision process
took into account the suggestion that apart from reasona-
bly high efficacies of partner drugs, an effective combina-
tion therapy should comprise of drugs that have not been
deployed previously in the area for use as monotherapies
[16]. Prior to the 2006 policy change AQ was being used
as a second line antimalarial drug in Tanzania. Finally, AL
was highly recommended based on its extra privileges
such as being the only co-formulated ACT at the time of
policy change and good effectiveness parameters in the
country[17]. All these experience have paved the way for
adoption of AL as the first line antimalarial drug in Tanza-
nia.
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